①Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
 心房細動患者における PCI 後のダビガトランを用いた抗血栓薬 2 剤併用療法

②Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
 TNF 阻害薬の効果が不十分な乾癬性関節炎患者に対するトファシチニブ

③Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

④Effect of a Hospital-wide Measure on the Readmissions Reduction Program


①,Dual Antithrombotic Therapy,抗血栓薬 2 剤併用療法
①,patients with atrial fibrillation,心房細動患者
①,Triple antithrombotic therapy,抗血栓薬 3 剤併用療法
①,this therapy is associated with a high risk of bleeding,この療法は出血のリスクが高いことに関連している
①,multicenter trial,多施設共同試験
①,P2Y12 inhibitor,P2Y12 阻害薬
①,triple-therapy group,3 剤併用療法群
①,dual therapy,2 剤併用療法群
①,clinically relevant nonmajor bleeding event,臨床的に重要な出血イベント
①,(both doses combined),(両用量群を統合)
①,incidence of a composite efficacy end point,有効性の複合エンドポイントの発生率
①,unplanned revascularization,予定外の血行再建
①,P<0.001 for noninferiority,非劣性の P<0.001
①,P<0.001 for superiority,優越性の P<0.001
①,Among patients with atrial fibrillation who had undergone PCI,PCI を受けた心房細動患者において,
②,Psoriatic Arthritis,乾癬性関節炎
②,Psoriatic Arthritis in Patients with an Inadequate Response to,の効果が不十分な乾癬性関節炎患者
②,TNF Inhibitors,TNF 阻害薬
②,oral Janus kinase inhibitor,経口ヤヌスキナーゼ阻害薬
②,patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors,腫瘍壊死因子(TNF)阻害薬の効果が不十分であったコントロール不良の乾癬性関節炎患者
②,tumor necrosis factor (TNF) inhibitors,腫瘍壊死因子(TNF)阻害薬
②,Data from the patients who received placebo during the first 3 months of the trial were pooled. ,試験開始後 3 ヵ月間プラセボを投与された患者のデータを統合した.
②,percentage of patients who had at least 20% improvement according to the criteria of the American College of Rheumatology (ACR20 response),米国リウマチ学会基準による 20%以上の改善(ACR20 改善)を達成した患者の割合
②, criteria of the American College of Rheumatology,米国リウマチ学会基準
②,Health Assessment Questionnaire,健康評価質問票
②,Disability Index,機能障害指数
②,rates of ACR20 response,ACR20 改善率
②,herpes zoster infections,帯状疱疹
②,aspartate and alanine aminotransferase concentrations,アスパラギン酸アミノトランスフェラーゼ値とアラニンアミノトランスフェラーゼ値
②,upper limit of the normal range,正常上限値
②,disease activity,疾患活動性
③,patients with active psoriatic arthritis,乾癬性関節炎患者
③,conventional synthetic disease-modifying antirheumatic drugs,従来の合成疾患修飾性抗リウマチ薬
③,synthetic disease-modifying antirheumatic drugs,合成疾患修飾性抗リウマチ薬
③,placebo with a blinded switch to the 5-mg tofacitinib dose at 3 months,プラセボを投与し 3 ヵ月の時点で盲検下でトファシチニブ 10 mg に切り替える群
③,American College of Rheumatology 20 (ACR20) response,ACR20 改善
③,圧痛関節数,number of tender joints
③,腫脹関節数,number of swollen joints
④,Hospital-wide Measure,病院全体の指標
④,Readmissions Reduction Program,再入院削減プログラム
④,30-day readmission rates,30 日再入院率
④,across specific conditions,特定疾患について
④,safety-net hospitals,セーフティネット病院